Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency.

Shamima Rahman,S. MacDonald‐Hull,M. Lewis‐Jones,Sanjiv Manek,G. Guillet,Robert Mann,L. J. Cook,A. Highet,Nigel Burrows,S. E. Hadfield-Jones,H. Mcgrath,P. Morrison,F. Camacho-Martínez,S. Jabłońska,R. Ratnavel,R. Charles-Holmes,B. Daly,M. Crone,N. Hardwick,Stewart Fleming,Andrew Rowan,M. Mitchell,S. Adams,E. Potts,D. Kelsell,K. Grice,Patrick J. Pollard,S. Wilkinson,S. Olpin,Eduardo Calonje,N. A. Alam,E. Barclay,M. Keefe,D. Seukeran,Ian Tomlinson,J. Tyrer,G. Ford,L. Fuller,Alastair A. Macdonald,Philip Bowers,N. Wortham,Irene M. Leigh

DOI: https://doi.org/10.1093/HMG/DDG148

IF: 5.1214

2003-06-01

Human Molecular Genetics

Abstract:Germline mutations of the fumarate hydratase (FH, fumarase) gene are found in the recessive FH deficiency syndrome and in dominantly inherited susceptibility to multiple cutaneous and uterine leiomyomatosis (MCUL). We have previously reported a number of germline FH mutations from MCUL patients. In this study, we report additional FH mutations in MCUL and FH deficiency patients. Mutations can readily be found in about 75% of MCUL cases and most cases of FH deficiency. Some of the more common FH mutations are probably derived from founding individuals. Protein-truncating FH mutations are functionally null alleles. Disease-associated missense FH changes map to highly conserved residues, mostly in or around the enzyme's active site or activation site; we predict that these mutations severely compromise enzyme function. The mutation spectra in FH deficiency and MCUL are similar, although in the latter mutations tend to occur earlier in the gene and, perhaps, are more likely to result in a truncated or absent protein. We have found that not all mutation-carrier parents of FH deficiency children have a strong predisposition to leiomyomata. We have confirmed that renal carcinoma is sometimes part of MCUL, as part of the variant hereditary leiomyomatosis and renal cancer (HLRCC) syndrome, and have shown that these cancers may have either type II papillary or collecting duct morphology. We have found no association between the type or site of FH mutation and any aspect of the MCUL phenotype. Biochemical assay for reduced FH functional activity in the germline of MCUL patients can indicate carriers of FH mutations with high sensitivity and specificity, and can detect reduced FH activity in some patients without detectable FH mutations. We conclude that MCUL is probably a genetically homogeneous tumour predisposition syndrome, primarily resulting from absent or severely reduced fumarase activity, with currently unknown functional consequences for the smooth muscle or kidney cell.

Medicine,Biology

What problem does this paper attempt to address?

Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency.

A Missense Mutation c.1132G > A in Fumarate Hydratase (FH) Leads to Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Syndrome and Insights into Clinical Management in Uterine Leiomyomata

Segregation, immunohistochemical, molecular and functional analyses classify a novel missense variant in fumarate hydratase (FH) as pathogenic

A new missense mutation c.1240A>G in fumarate hydratase gene leads to uterine leiomyoma associated hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome in Chinese

Functional Characterization of FH Mutation c.557G>A Underlies Uterine Leiomyomas.

Clinicopathological and Molecular Characteristics of Fumarate Hydratase-Deficient Uterine Smooth Muscle Tumors: a Single-Center Study of 52 Cases

The Use of Clinicopathological, Immunohistochemistry and molecular detection in the diagnosis of Fumarate Hydratase-Deficient Uterine Leiomyomas

[Fumarate Hydratase Deficient Uterine Leiomyoma: a Clinicopathological and Molecular Analysis of 80 Cases].

Benign metastasizing fumarate hydratase (FH)-deficient uterine leiomyomas: clinicopathological and molecular study with first documentation of multi-organ metastases

Chromatin Helicase CHD6 Establishes Pro-inflammatory Enhancers and is a Synthetic Lethal Target in FH-Deficient Renal Cell Carcinoma.

A Novel Nonsense Mutation in the Fumarate Hydratase Gene in a Chinese Patient with Recurrent Leiomyomas

Fumaratehydratase-deficient Renal Cell Carcinoma: a Clinicopathological and Molecular Study of 13 Cases

FH variant pathogenicity promotes purine salvage pathway dependence in kidney cancer

An octad of fumarate hydratase-deficient uterine leiomyomas: Case series with review of literature from a single institution

Fumarate Hydratase Mutations and Alterations in Leiomyoma With Bizarre Nuclei

Genome-wide linkage and association analyses implicate FASN in predisposition to Uterine Leiomyomata

Genetic and clinical characterization of a novel FH founder mutation in families with hereditary leiomyomatosis and renal cell cancer syndrome

Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC): Case Series and Review of the Literature

Fine Mapping of the Uterine Leiomyoma Locus on 1q43 Close to a Lncrna in the RGS7-FH Interval

Multi-omics Analyses and Molecular Subtypes to Provide Potential Therapeutic Implications in Fumarate Hydratase-Deficient Renal Cell Carcinoma.

Identification of a Novel Mutation at the Point of Low Density Lipoprotein Receptor Gene from a Subject with Familial Hypercholesterolemia